Some members of a Food and Drug Administration advisory panel had questions and others didn’t about HRA Pharma’s actual user study data but all voted to recommend the agency approve the firm’s proposal for the first OTC switch of an oral contraceptive in the US.
FDA officials again made clear their concerns about “improbable dosing” data in HRA’s supplement new drug application for its 0.075-mg...